Radiotherapy and Immunotherapy Combinations for Lung Cancer

Area of Science:

• Oncology
• Immunology
• Radiation Oncology

Background:

• Immunotherapy has become a cornerstone in non-small cell lung cancer (NSCLC) treatment, with several agents approved for various stages.
• Radiation therapy (RT) is increasingly recognized for its potential to modulate the tumor immune microenvironment.
• Recent clinical trials highlight the synergistic potential of combining immunotherapy and RT.

Purpose of the Study:

• To review key clinical findings on the impact of radiation therapy on tumor immunity in NSCLC.
• To summarize ongoing efforts and the promise of combining immunotherapy and RT for NSCLC treatment.

Main Methods:

• Review of recent clinical trial data and literature on immunotherapy and radiation therapy in NSCLC.
• Analysis of the immunological effects of RT in the context of NSCLC.

Main Results:

• Immunotherapy approvals (nivolumab, pembrolizumab, durvalumab, atezolizumab) have expanded NSCLC treatment options.
• Early-phase trials demonstrate RT's ability to induce clinically significant tumor immunity.
• Current trials combining RT and immunotherapy for NSCLC are showing promising results.

Conclusions:

• The combination of RT and immunotherapy holds significant promise for improving NSCLC treatment outcomes.
• Careful patient selection will be crucial for optimizing therapeutic benefits and achieving meaningful clinical improvements.
• Further research and clinical trials are warranted to establish the optimal use of combined RT and immunotherapy in NSCLC.